{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:37:18Z","timestamp":1771511838229,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007911","name":"University of California, San Diego","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007911","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Metabolism"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.molmet.2020.101039","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T21:05:06Z","timestamp":1591823106000},"page":"101039","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2\u03b1-dependent mechanism"],"prefix":"10.1016","volume":"41","author":[{"given":"Matthew","family":"Riopel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Su","family":"Moon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gautam K.","family":"Bandyopadhyay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seohee","family":"You","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Lam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Kisseleva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7967-4734","authenticated-orcid":false,"given":"Yun Sok","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.molmet.2020.101039_bib1","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1007\/s00125-016-3965-9","article-title":"Glucagon is the key factor in the development of diabetes","volume":"59","author":"Lee","year":"2016","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.molmet.2020.101039_bib2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI60016","article-title":"Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover","volume":"122","author":"Unger","year":"2012","journal-title":"Journal of Clinical Investigation"},{"issue":"5","key":"10.1016\/j.molmet.2020.101039_bib3","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1111\/dom.13202","article-title":"Effect of a glucagon receptor antibody (REMD-477) in type 1 diabetes: a randomized controlled trial","volume":"20","author":"Pettus","year":"2018","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib4","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1111\/dom.12446","article-title":"Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes","volume":"17","author":"Kelly","year":"2015","journal-title":"Diabetes, Obesity and Metabolism"},{"issue":"7","key":"10.1016\/j.molmet.2020.101039_bib5","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.2337\/dc15-1643","article-title":"Evaluation of efficacy and safety of the glucagon receptor antagonist LY2409021 in patients with type 2 diabetes: 12- and 24-week phase 2 studies","volume":"39","author":"Kazda","year":"2016","journal-title":"Diabetes Care"},{"issue":"7","key":"10.1016\/j.molmet.2020.101039_bib6","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dci15-0033","article-title":"Clinical trials, triumphs, and tribulations of glucagon receptor antagonists","volume":"39","author":"Pearson","year":"2016","journal-title":"Diabetes Care"},{"issue":"8","key":"10.1016\/j.molmet.2020.101039_bib7","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1073\/pnas.1424934112","article-title":"Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway","volume":"112","author":"Wang","year":"2015","journal-title":"Proceedings of the National Academy of Sciences of the U S A"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib8","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.2337\/db11-1605","article-title":"Liver-specific disruption of the murine glucagon receptor produces alpha-cell hyperplasia: evidence for a circulating alpha-cell growth factor","volume":"62","author":"Longuet","year":"2013","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib9","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.immuni.2014.09.008","article-title":"HIF transcription factors, inflammation, and immunity","volume":"41","author":"Palazon","year":"2014","journal-title":"Immunity"},{"issue":"10","key":"10.1016\/j.molmet.2020.101039_bib10","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.2337\/db11-0174","article-title":"Disruption of hypoxia-inducible factor 1 in adipocytes improves insulin sensitivity and decreases adiposity in high-fat diet-fed mice","volume":"60","author":"Jiang","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cmet.2011.08.006","article-title":"The differential role of Hif1beta\/Arnt and the hypoxic response in adipose function, fibrosis, and inflammation","volume":"14","author":"Lee","year":"2011","journal-title":"Cell Metabolism"},{"issue":"6","key":"10.1016\/j.molmet.2020.101039_bib12","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/j.cell.2014.05.012","article-title":"Increased adipocyte O2 consumption triggers HIF-1alpha, causing inflammation and insulin resistance in obesity","volume":"157","author":"Lee","year":"2014","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.molmet.2020.101039_bib13","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1128\/MCB.00951-12","article-title":"Selective inhibition of hypoxia-inducible factor 1alpha ameliorates adipose tissue dysfunction","volume":"33","author":"Sun","year":"2013","journal-title":"Molecular and Cellular Biology"},{"issue":"10","key":"10.1016\/j.molmet.2020.101039_bib14","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1038\/nm.3294","article-title":"Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes","volume":"19","author":"Taniguchi","year":"2013","journal-title":"Nature Medicine"},{"issue":"7","key":"10.1016\/j.molmet.2020.101039_bib15","article-title":"Hepatocyte-specific HIF-1alpha ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation","volume":"5","author":"Lee","year":"2019","journal-title":"Science Advance"},{"issue":"3","key":"10.1016\/j.molmet.2020.101039_bib16","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.cmet.2016.01.004","article-title":"HIF2alpha is an essential molecular brake for postprandial hepatic glucagon response independent of insulin signaling","volume":"23","author":"Ramakrishnan","year":"2016","journal-title":"Cell Metabolism"},{"issue":"10","key":"10.1016\/j.molmet.2020.101039_bib17","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1038\/nm.3295","article-title":"A\u00a0liver Hif-2alpha-Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition","volume":"19","author":"Wei","year":"2013","journal-title":"Nature Medicine"},{"issue":"8","key":"10.1016\/j.molmet.2020.101039_bib18","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1038\/s41374-019-0239-4","article-title":"Inhibition of prolyl hydroxylase domain (PHD) by JTZ-951 reduces obesity-related diseases in the liver, white adipose tissue, and kidney in mice with a high-fat diet","volume":"99","author":"Saito","year":"2019","journal-title":"Laboratory Investigation"},{"issue":"10","key":"10.1016\/j.molmet.2020.101039_bib19","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db14-0472","article-title":"HIF prolyl 4-hydroxylase-2 inhibition improves glucose and lipid metabolism and protects against obesity and metabolic dysfunction","volume":"63","author":"Rahtu-Korpela","year":"2014","journal-title":"Diabetes"},{"issue":"39","key":"10.1016\/j.molmet.2020.101039_bib20","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1093\/eurheartj\/ehw156","article-title":"Deficiency of the oxygen sensor prolyl hydroxylase 1 attenuates hypercholesterolaemia, atherosclerosis, and hyperglycaemia","volume":"37","author":"Marsch","year":"2016","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1016\/j.molmet.2020.101039_bib21","doi-asserted-by":"crossref","first-page":"E261","DOI":"10.1152\/ajpendo.00676.2007","article-title":"Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice","volume":"294","author":"Lee","year":"2008","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"10","key":"10.1016\/j.molmet.2020.101039_bib22","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.2337\/db11-0194","article-title":"Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance","volume":"60","author":"Lee","year":"2011","journal-title":"Diabetes"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib23","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1172\/JCI94330","article-title":"Chronic fractalkine administration improves glucose tolerance and pancreatic endocrine function","volume":"128","author":"Riopel","year":"2018","journal-title":"Journal of Clinical Investigation"},{"issue":"9","key":"10.1016\/j.molmet.2020.101039_bib24","doi-asserted-by":"crossref","first-page":"2176","DOI":"10.1210\/me.2008-0023","article-title":"Dysregulation of adipose glutathione peroxidase 3 in obesity contributes to local and systemic oxidative stress","volume":"22","author":"Lee","year":"2008","journal-title":"Molecular Endocrinology"},{"key":"10.1016\/j.molmet.2020.101039_bib25","doi-asserted-by":"crossref","DOI":"10.1038\/s42255-018-0003-x","article-title":"Knockdown of ANT2 reduces adipocyte hypoxia and improves insulin resistance in obesity","author":"Seo","year":"2018","journal-title":"Nature Metabolism"},{"issue":"1","key":"10.1016\/j.molmet.2020.101039_bib26","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.cmet.2008.06.006","article-title":"Inactivation of hepatic Foxo1 by insulin signaling is required for adaptive nutrient homeostasis and endocrine growth regulation","volume":"8","author":"Dong","year":"2008","journal-title":"Cell Metabolism"},{"issue":"9","key":"10.1016\/j.molmet.2020.101039_bib27","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI200112876","article-title":"The forkhead transcription factor Foxo1 (Fkhr) confers insulin sensitivity onto glucose-6-phosphatase expression","volume":"108","author":"Nakae","year":"2001","journal-title":"Journal of Clinical Investigation"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrd4228","article-title":"Advances in targeting cyclic nucleotide phosphodiesterases","volume":"13","author":"Maurice","year":"2014","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1016\/j.molmet.2020.101039_bib29","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/S0955-0674(99)00073-3","article-title":"Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions","volume":"12","author":"Soderling","year":"2000","journal-title":"Current Opinion in Cell Biology"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib30","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cmet.2017.03.004","article-title":"Imbalanced insulin actions in obesity and type 2 diabetes: key mouse models of insulin signaling pathway","volume":"25","author":"Kubota","year":"2017","journal-title":"Cell Metabolism"},{"issue":"16","key":"10.1016\/j.molmet.2020.101039_bib31","doi-asserted-by":"crossref","first-page":"6964","DOI":"10.1021\/acs.jmedchem.7b01686","article-title":"Prolyl hydroxylase inhibitors: a breakthrough in the therapy of anemia associated with chronic diseases","volume":"61","author":"Joharapurkar","year":"2018","journal-title":"Journal of Medicinal Chemistry"},{"issue":"6","key":"10.1016\/j.molmet.2020.101039_bib32","doi-asserted-by":"crossref","first-page":"982","DOI":"10.2215\/CJN.06890615","article-title":"Oral hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat (FG-4592) for the treatment of anemia in patients with CKD","volume":"11","author":"Provenzano","year":"2016","journal-title":"Clinical Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1016\/j.molmet.2020.101039_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1358863X14557151","article-title":"Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease","volume":"19","author":"Olson","year":"2014","journal-title":"Vascular Medicine"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib34","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1161\/ATVBAHA.115.307136","article-title":"Hypoxia-inducible factor prolyl 4-hydroxylase-2 inhibition protects against development of atherosclerosis","volume":"36","author":"Rahtu-Korpela","year":"2016","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"5","key":"10.1016\/j.molmet.2020.101039_bib35","doi-asserted-by":"crossref","DOI":"10.3390\/cells8050384","article-title":"Protein hydroxylation by hypoxia-inducible factor (HIF) hydroxylases: unique or ubiquitous?","volume":"8","author":"Strowitzki","year":"2019","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.molmet.2020.101039_bib36","doi-asserted-by":"crossref","first-page":"14290","DOI":"10.1038\/s41598-018-32575-z","article-title":"PHD3 regulates glucose metabolism by suppressing stress-induced signalling and optimising gluconeogenesis and insulin signalling in hepatocytes","volume":"8","author":"Yano","year":"2018","journal-title":"Scientific Reports"},{"issue":"4","key":"10.1016\/j.molmet.2020.101039_bib37","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1515\/hsz-2012-0328","article-title":"Hypoxia-inducible factor prolyl 4-hydroxylases: common and specific roles","volume":"394","author":"Myllyharju","year":"2013","journal-title":"Biological Chemistry"},{"issue":"21","key":"10.1016\/j.molmet.2020.101039_bib38","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1161\/CIRCULATIONAHA.113.001742","article-title":"Prolyl hydroxylase domain protein 2 plays a critical role in diet-induced obesity and glucose intolerance","volume":"127","author":"Matsuura","year":"2013","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.molmet.2020.101039_bib39","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.molmet.2014.05.007","article-title":"ERalpha upregulates Phd3 to ameliorate HIF-1 induced fibrosis and inflammation in adipose tissue","volume":"3","author":"Kim","year":"2014","journal-title":"Molecular Metabolism"},{"issue":"5","key":"10.1016\/j.molmet.2020.101039_bib40","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1002\/hep.24256","article-title":"Hepatocyte-specific hypoxia-inducible factor-1alpha is a determinant of lipid accumulation and liver injury in alcohol-induced steatosis in mice","volume":"53","author":"Nath","year":"2011","journal-title":"Hepatology"}],"container-title":["Molecular Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301137?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212877820301137?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:22:57Z","timestamp":1761956577000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212877820301137"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":40,"alternative-id":["S2212877820301137"],"URL":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101039","relation":{},"ISSN":["2212-8778"],"issn-type":[{"value":"2212-8778","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of prolyl hydroxylases increases hepatic insulin and decreases glucagon sensitivity by an HIF-2\u03b1-dependent mechanism","name":"articletitle","label":"Article Title"},{"value":"Molecular Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmet.2020.101039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"101039"}}